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Parkinson’s disease (PD) is characterized by a progressive loss of
dopaminergic neurons, a process that current therapeutic approaches
cannot prevent. In PD, the typical pathological hallmark is the accu-
mulation of intracellular protein inclusions, known as Lewy bodies
and Lewy neurites, which are mainly composed of α-synuclein. Here,
we exploited a high-throughput screeningmethodology to identify a
small molecule (SynuClean-D) able to inhibit α-synuclein aggregation.
SynuClean-D significantly reduces the in vitro aggregation of wild-
type α-synuclein and the familiar A30P and H50Q variants in a sub-
stoichiometric molar ratio. This compound prevents fibril propagation
in protein-misfolding cyclic amplification assays and decreases the
number of α-synuclein inclusions in human neuroglioma cells. Com-
putational analysis suggests that SynuClean-D can bind to cavities in
mature α-synuclein fibrils and, indeed, it displays a strong fibril disag-
gregation activity. The treatment with SynuClean-D of two PD Caeno-
rhabditis elegans models, expressing α-synuclein either in muscle or in
dopaminergic neurons, significantly reduces the toxicity exerted by
α-synuclein. SynuClean-D–treated worms show decreased α-synuclein
aggregation in muscle and a concomitant motility recovery. More im-
portantly, this compound is able to rescue dopaminergic neurons from
α-synuclein–induced degeneration. Overall, SynuClean-D appears to
be a promising molecule for therapeutic intervention in Parkinson’s
disease.
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Parkinson’s disease (PD) is the second most prevalent neu-rodegenerative disorder after Alzheimer’s disease (AD) and
is still incurable (1). PD is the most common synucleinopathy, a
group of neurodegenerative disorders that includes dementia with
Lewy bodies and multiple system atrophy (MSA), among others (2,
3). Although the synucleinopathies are multifactorial disorders, the
molecular events triggering the pathogenic breakthrough of the
disease converge to the abnormal aggregation of α-synuclein (α-Syn)
in dopaminergic neurons (4, 5). α-Syn aggregation also occurs in
oligodendrocytes in patients with MSA (6). α-Syn is an intrinsically
disordered protein, which is expressed at high levels in the brain.
α-Syn function is thought to be related to vesicle trafficking (7). This
wild-type protein is the main component of cytoplasmic Lewy bodies
(LB) and Lewy neurites (LN) in sporadic PD (8). In addition,
dominantly inherited mutations in α-Syn, as well as multiplications of
the gene encoding for α-Syn (SNCA), cause familial forms of PD (9).
Interfering with α-Syn aggregation has been envisioned as a
promising disease-modifying approach for the treatment of PD
(1). However, the disordered nature of α-Syn precludes the use of
structure-based drug design for the discovery of novel molecules
able to modulate α-Syn aggregation. Therefore, many efforts have
focused on the analysis of large collections of chemically diverse
molecules to identify lead compounds (10). Recently, we have
developed an accurate and robust high-throughput screening
methodology to identify α-Syn aggregation inhibitors (11). Here,
we describe the properties of SynuClean-D (SC-D), a small mol-
ecule identified with this approach (SI Appendix, Fig. S1). We first
performed a detailed in vitro biophysical characterization of the
inhibitory and disaggregation activities of SC-D and tested its
performance in human neural cells. Finally, we validated the ef-
fects in vivo in two well-established Caenorhabditis elegans models
of PD, which express α-Syn either in muscle cells or in dopaminergic
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neurons. The inhibitor reduced α-Syn aggregation, improved
motility, and protected against neuronal degeneration.
Results
SynuClean-D Inhibits α-Syn Aggregation in Vitro. The formation of
α-Syn amyloid fibrils can be reproduced in vitro by incubating the
recombinant protein. However, fibril growth is very slow and highly
variable, complicating drug screening (12). We have implemented
a robust high-throughput kinetic assay to screen large chemical li-
braries in the search for α-Syn aggregation inhibitors (11). The assay
uses thioflavin-T (Th-T) as readout of amyloid formation, com-
pleting highly reproducible reactions in 30 h. Approximately 14,400
chemically diverse compounds of the HitFinder Collection from
Maybridge were screened with this approach. SC-D [2-hydroxy-5-
nitro-6-(3-nitrophenyl)-4-(trifluoromethyl)nicotinonitrile], a small
aromatic compound, was identified as one of the molecules of
potential interest (SI Appendix, Fig. S1). Many compounds with
promising pharmacological characteristics never become drugs
because they are rapidly metabolized in the liver and therefore
have low oral bioavailability. SC-D was metabolically stable in the
presence of human hepatic microsomes, with an intrinsic clear-
ance of <5 μL·min−1·mg−1 (SI Appendix, Fig. S2).
Incubation of 70 μM α-Syn with 100 μM SC-D impacted α-Syn
aggregation, as monitored by Th-T fluorescence (Fig. 1A). The
analysis of the aggregation curves indicated that the autocatalytic
rate constant in the presence of the compound (ka 0.25 h
−1) was
25% lower than in its absence (ka 0.33 h
−1). SC-D increases t50 by
1.5 h and reduces by 53% the amount of Th-T–positive material
at the end of the reaction. By measuring light scattering, we
confirmed that the observed changes in Th-T fluorescence
reflected an effective decrease in the levels of α-Syn aggregates,
with a reduction of 48 and 58% in the scattering signal at the end
of the reaction in the presence of SC-D when exciting at 300 and
340 nm, respectively (Fig. 1B). Nanoparticle tracking analysis
indicated that the presence of SC-D increased the number of
particles of <100 nm and decreased the formation of large ag-
gregates (150 to 500 nm) (SI Appendix, Fig. S3). Finally, trans-
mission electron microscopy (TEM) images confirmed that samples
incubated with SC-D contained smaller and much fewer fibrils per
field than untreated samples (Fig. 1 C and D). The inhibitory ac-
tivity of SC-D was dose-dependent and still statistically significant at
10 μM (1:7 compound:α-Syn ratio), where it reduces the final Th-T
signal by 34% (Fig. 1E).
We further investigated whether SC-D was active against the
aggregation of α-Syn variants associated with PD (1). SC-D was
able to reduce by 45 and 73% the amount of Th-T–positive ag-
gregates at the end of the reaction for the H50Q and A30P α-Syn
familial variants, respectively (Fig. 1F).
The inhibitory activity of SC-D was also assessed using
protein-misfolding cyclic amplification (PMCA) (13). Concep-
tually based on the nucleation-dependent polymerization model
for prion replication, PMCA has been recently adapted to am-
plify α-Syn amyloid fibrils (14). The PMCA technique combines
cycles of incubation at 37 °C, to grow fibrils, and sonication, to
break fibrils into smaller seeds. In our conditions, a single cycle
of amplification was sufficient to generate amyloid-like protease
K (PK)-resistant α-Syn assemblies, but the highest levels of
protection were attained after four rounds (Fig. 1G). When the
same experiment was performed in the presence of SC-D, we
observed a substantial decrease in the amount of PK-resistant
material (Fig. 1H), indicating that the molecule was interfering
with α-Syn template seeding amyloid formation.
SynuClean-D Disrupts Preformed α-Syn Fibrils. The progress of
α-Syn PMCA reactions can also be monitored by using the Th-T
signal as the readout for fibril assembly (15). Consistent with PK
resistance analysis, Th-T fluorescence of α-Syn increased signif-
icantly after four cycles of PMCA (Fig. 2A). Surprisingly, in the
presence of SC-D, the Th-T signal not only did not increase, but
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Fig. 1. Effect of SynuClean-D on the aggregation of α-Syn in vitro. (A) α-Syn aggregation kinetics in the absence (black) and presence (blue) of SC-D followed
by Th-T–derived fluorescence. (B) Light-scattering signal at 300 and 340 nm, both in the absence (white) and presence (blue) of SC-D. (C and D) Representative
TEM images in the absence (C) and presence (D) of SC-D. (E) Inhibition of α-Syn aggregation in the presence of different concentrations of SC-D. (F) H50Q and
A30P α-Syn variant aggregation in the absence (white) and presence (blue) of SC-D. (G and H) Bis/Tris gels of PMCA samples in the absence (G) and presence
(H) of SC-D, both analyzed after PK digestion. Soluble α-Syn and PMCA steps 4 and 5 are shown. Th-T fluorescence is plotted as normalized means. Final points
were obtained at 48 h. Error bars are represented as SE of mean values; **P < 0.01 and ***P < 0.001.
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began to decrease after the third cycle. This suggested that SC-D
might disrupt newly formed amyloid fibrils.
To address the time window in which SC-D is active, we set up
aggregation reactions with a constant amount of SC-D at dif-
ferent time intervals. As presented in Fig. 2B, the effect of SC-D
on the final amount of amyloid structures was independent of
whether it was added at the beginning (4 h), in the middle (12 h),
or at the end (18 h) of the exponential phase, or even when the
reaction had already attained a plateau (24 h). These results
suggested again ability to disrupt/destabilize fibrils.
To confirm the fibril-disrupting activity of SC-D, 4-d mature α-Syn
fibrils were incubated in the absence or presence of the compound
for 24 h. Incubation with SC-D promoted a 43% reduction in Th-T
fluorescence emission (Fig. 2C). Moreover, light-scattering mea-
surements indicated a reduction in the amount of detectable ag-
gregates by 29 and 39% at 300 and 340 nm, respectively (Fig. 2D).
Consistently, TEM images illustrated how 4-d-incubated α-Syn
tended to form big fibrillary clusters (Fig. 2E), which became
completely disrupted in the presence of SC-D (Fig. 2F).
α-Syn Fibrils Can Accommodate SynuClean-D. To assess if SC-D can
bind monomeric and soluble α-Syn, the recombinant protein was
isotopically labeled and NMR 1H-15N-HSQC spectra of 70 μM
[15N]α-Syn were recorded in the absence and presence of SC-D.
We did not detect any perturbations in chemical shifts or peak
intensities with respect to the original α-Syn spectrum in the
presence of 100 μM concentration of the molecule (SI Appendix,
Fig. S4), indicating that SC-D does not bind α-Syn monomers.
Induced-fit docking simulations of α-Syn–SC-D revealed four
major poses for its interaction with α-Syn fibrils (16): two internal,
with SC-D fully inserted in the fibril (poses 1 and 2), and two
external, with SC-D partially exposed (poses 3 and 4) (SI Ap-
pendix, Fig. S5). In the internal poses, the ligand is sandwiched
between two parallel β-sheets of the Greek-key motif and interacts
with the side chains of ALA53, VAL55, THR59, GLU61, THR72,
and GLY73. The only difference between pose 1 and 2 lies in the
orientation of the compound in the binding pocket. PELE (17)
interaction energies are stronger for the internal poses, where
SC-D binds essentially through dispersion interactions into a
solvent-excluded cavity, than for external ones, where SC-D in-
serts into a surface groove of the fibril. In light of these calcula-
tions, we predict that SC-D binds into the core of α-Syn fibrils.
MM/GBSA calculations (SI Appendix, Table S1) (18, 19) show
that internal binding pose 1 (Fig. 3) exhibits the largest binding
energy with the fibril, the computedΔGbind being −18.4 ± 4.1 kcal·
mol−1. The main contribution comes from the van der Waals term,
representing roughly 80% of the interaction. This is not surprising
given the nature of SC-D, a planar aromatic molecule. Plots of the
reduced density gradient versus the density (SI Appendix, Fig.
S6A) provide information on the nature of the noncovalent in-
teractions in the system (20). Peaks in the negative and positive
regions of the x axis are indicative of attractive and repulsive in-
teractions, respectively. The region around zero corresponds to
the weakest noncovalent van der Waals contacts. Though weak,
these interactions are present in large number and involve the
whole body of the molecule, being the largest contribution to the
binding energy. Their spatial extension is shown in SI Appendix,
Fig. S6B. For pose 1, the noncovalent interaction plot shows that
Fig. 2. Disaggregational capacity of SynuClean-D. (A) Th-T fluorescence of
the different PMCA passes of both treated (blue) and untreated (black)
samples with SC-D. (B) Aggregation kinetics of α-Syn after the addition of SC-
D at different time points. (C and D) Th-T–derived fluorescence (C) and light-
scattering (D) assays before and after the addition of SC-D to preformed
α-Syn fibrils. (E and F) Representative TEM images in the absence (E) and
presence (F) of SC-D. Th-T fluorescence is plotted as normalized means. Error
bars are represented as SE of mean values; ***P < 0.001.
Fig. 3. Characterization of SynuClean-D–fibril interaction. General view (A) and
zoom (B) of the most stable binding pose of SC-D on the α-Syn fibril model.








besides van der Waals, an H-bond contact is responsible for the
binding of SC-D (SI Appendix, Fig. S6A).
SynuClean-D Inhibits the Formation of Intracellular α-Syn Aggregates
in Cultured Cells. We tested the potential toxicity of SC-D for
human neuroglioma (H4) and human neuroblastoma (SH-SY5Y)
cells. For both cell lines, the molecule was innocuous at concen-
trations as high as 50 μM (Fig. 4A and SI Appendix, Fig. S7). We
used a well-established cell model that enabled us to assess α-Syn
inclusion formation. H4 cells were transiently transfected with
C-terminally modified α-Syn (synT) and synphilin-1, which results
in the formation of LB-like inclusions, as we previously described
(9). The formation of α-Syn inclusions was assessed 24 h after
treatment by immunofluorescence (Fig. 4D). Upon treatment with
1 and 10 μM SC-D, we observed a significant increase in the
number of transfected cells devoid of α-Syn inclusions (SC-D,
1 μM: 42.4 ± 1.0%; SC-D, 10 μM: 49.5 ± 4.5%) relative to un-
treated samples (control: 28.7 ± 2.0%) (Fig. 4B). SC-D treatment
also promoted a significant decrease in the number of transfected
cells displaying more than five aggregates (SC-D, 1 μM: 35.5 ±
5.0%; SC-D, 10 μM: 32.5 ± 6.6%) relative to control cells (con-
trol: 49.6 ± 5.6%) (Fig. 4C).
SynuClean-D Inhibits α-Syn Aggregation in a C. elegans Model of PD.
Next, we tested SC-D in a living system. We used a well-studied
nematode model of PD, the strain NL5901, in which human α-Syn
fused to the yellow fluorescent protein (YFP) is under control of
the muscular unc-54 promoter, transgene pkIs2386 [Punc-54::α-
SYN::YFP] (21). Muscle expression has been used successfully to
model protein-misfolding diseases and to identify modifier genes
without considering neuronal effects (21, 22). To determine the
effects of SC-D in α-Syn accumulations, animals at the fourth larval
stage (L4) (23) were incubated with and without the compound, to
analyze the inhibitor efficiency in aged worms at 9 d posthatching
(L4 + 7), which mimics aged human PD (24). We avoided a
compound burst at L1 (25) because this treatment mimics a
preventive rather than a disease-modifying intervention. Quan-
tification of the number of α-Syn aggregates revealed that, in
treated animals, the number of visible α-Syn aggregates de-
creased by 13.2 units, relative to untreated worms (18.3 ± 2.8 vs.
31.5 ± 1.1, respectively) (Fig. 5 A and D). In some animals,
treatment resulted in a near-complete loss of protein aggregates
(SI Appendix, Fig. S8). In this assay, SC-D is as effective as
epigallocatechin gallate (EGCG), a polyphenol able to inhibit
α-Syn aggregation and to disentangle preformed α-Syn aggre-
gates (26, 27). EGCG has also been shown to reduce the deposits
of the amyloid β-peptide in a C. elegans muscular model of AD
(28). In our PD model, EGCG treatment reduced the number of
visible aggregates by 13.4 units (18.1 ± 0.7) (Fig. 5A).
Major defects in regular bending have been used to identify
modifiers of protein aggregation (21). Indeed, C. elegans thrashing
can be measured in liquid media by counting the number of body
bends per unit of time (29). By using this method, we confirmed an
improved motility in SC-D–treated animals in comparison with
nontreated worms (Fig. 5 B and E). We observed a decrease of
bending of 72.2% in YFP::α-SYN animals compared with the N2
wild-type strain (18.1 ± 2.5 vs. 90.3 ± 6.7, respectively). This
motility decrease was reverted in YFP::α-SYN animals treated
with SC-D. In these animals, the average bending increased by 2.7-
fold, compared with nontreated animals (18.1 ± 2.5 vs. 49.1 ± 4.4)
(Movies S1 and S2).
SynuClean-D Prevents Degeneration of Dopaminergic Neurons in a C.
elegans Model of PD. PD is characterized by the degeneration of
dopaminergic (DA) neurons. There exist four pairs of DA neu-
rons in C. elegans hermaphrodites, three of them (CEPD, CEPV,
and ADE) located in the anterior part, and one pair, the PDE, in
the posterior part of the nematode (30). To investigate the
neuroprotective role of SC-D in dopaminergic cell death, we
sought to analyze its effect in a C. elegans model of PD in which
DA neurons undergo age-dependent neurodegeneration (31). In
this model (strain UA196), animals express both human α-Syn
and GFP in DA neurons, according to the simplified genotype
Pdat-1::GFP; Pdat-1::α-SYN (the full genotype is detailed in SI
Appendix). This strain has been successfully used for the in-
vestigation of human PD-related mechanisms (24). When human
α-Syn is expressed in these animals’ DA neurons, the six DA
neurons within the anterior region of the worm display pro-
gressive degenerative characteristics (32). To model the aging
contribution to PD, we determined the inhibitor capacity of SC-
D in dealing with DA cell death induced by human α-Syn at 9 d
(L4 + 7) posthatching. Cell bodies and neuronal processes were
assessed to determine whether these structures displayed mor-
phology changes. At 9 d posthatching, only 14.0 ± 1.5% of
nontreated animals showed six wild-type DA neurons. In con-
trast, 44.4 ± 2.8% of treated animals showed the six intact DA
neurons (Fig. 5 C and F), which evidenced the ability of SC-D to
protect against α-Syn–induced DA neuron degeneration. In
contrast to SC-D, the administration of EGCG did not have any
beneficial impact on neurodegeneration, since only 12.0 ± 0.8%
of EGCG-treated animals exhibited six intact DA neurons, a
proportion that is fairly similar to that in untreated worms
(14.0 ± 1.5%) (Fig. 5C).
Discussion
α-Syn aggregation plays a major pathophysiological role in the
development of PD. Since its discovery and subsequent identi-
fication as the most abundant protein in Lewy bodies (3), α-Syn
was shown to be important for a number of cellular processes
(7). Therapeutic strategies targeting the aggregation of α-Syn
thus hold the promise to result in disease modification and
mitigate pathology in PD (33).
Fig. 4. Inhibition of α-Syn aggregate formation in cultured cells. (A) Human
neuroglioma cell (H4) survival when incubated with different concentrations
of compound (blue) and without (white) the compound. (B and C) Reduction
of α-Syn inclusion formation in human cultured cells in the presence of
different concentrations of SC-D. (B) Percentage of transfected cells devoid
of α-Syn aggregates. (C) Percentage of transfected cells bearing >5 α-Syn
aggregates. (D) Representative epifluorescent images from cells treated with
SC-D. n = 3. (Scale bar, 30 μm.) Error bars are represented as SE of means;
*P < 0.05 and **P < 0.01.
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The screening of large chemical libraries has rendered prom-
ising molecules that inhibit the progression of PD by targeting the
aggregation of α-Syn, like BIOD303 (34) or anle138b (35). Here,
by exploiting a previously developed high-throughput methodol-
ogy, we identified SC-D as a metabolically stable compound able
to inhibit >50% of α-Syn amyloid formation in vitro when
employed in a 0.7:1 (protein:SC-D) ratio. The ability of SC-D to
inhibit α-Syn aggregation was confirmed by light-scattering and
TEM assays. SC-D was also active against the aggregation of
α-Syn mutants that cause familial forms of the disease.
The activity of SC-D was concentration-dependent and still evident
at a substoichiometric 7:1 protein:compound ratio. This already sug-
gested that, unlike other compounds, SC-D does not bind to mono-
meric α-Syn, supported by NMR experiments. From a therapeutic
perspective, this is an important advantage, as SC-D is not expected
to interfere with the physiological functions of the soluble protein.
PMCA experiments indicated that SC-D might disrupt α-Syn
amyloid assemblies, a property that was confirmed by the ability
of SC-D to reduce the amount of formed amyloid fibrils, almost
independent of the stage of the aggregation reaction at which it
was added. Indeed, SC-D is very effective at disassembling
clusters of aged α-Syn amyloid fibrils, conceptually similar to the
α-Syn amyloid inclusions recurrently observed in the dopami-
nergic neurons of PD patients. This is important, because the
disassembly of preformed amyloid fibrils has been traditionally
challenging, and very few molecules have been reported to break
down amyloid fibrils (27) because of their high stability. Com-
putational analysis suggests that the disrupting activity of SC-D is
mediated by its binding to an inner cavity in α-Syn fibrils. The
disassembly of large fibrils has been seen traditionally as a risky
strategy for the amelioration of aggregation-linked diseases,
because it may increase the population of smaller toxic species
Fig. 5. Inhibition effect of the compound in the formation of α-Syn inclusions and protection from the α-Syn–induced dopaminergic cell death in C. elegans models
of PD. (A) Quantification of α-Syn muscle inclusions per area of NL5901 worms in the absence (white) and presence of SC-D (blue) or EGCG (gray). (B) Worm-thrashing
representation as the number of bends per minute of N2 wild-type and NL5901 worms treated without (white) and with SC-D (blue). (C) Percentage of UA196 worms
that maintain a complete set of dopaminergic neurons (four pairs located in the head) after treatment without (white) and with SC-D (blue) or EGCG (gray) for 7 d
after the L4 stage. (D) Representative images of α-Syn muscle aggregates obtained by epifluorescence microscopy of NL5901 worms treated without (Top, vehicle)
and with SC-D (Bottom, drug). (Scale bars, 10 μm.) Between 40 and 50 animals were analyzed per condition. Aggregates are indicated by white arrows. (E) Path
representation of the mobility of N2 wild-type (Left, vehicle) and NL5901 worms grown without (Middle, vehicle) and with SC-D (Right, drug). (Scale bars, 1 mm.)
(F) Representative worms expressing GFP–α-Syn specifically in DA neurons without (Left, vehicle) and with SC-D (Right, drug) for 7 d after L4. Healthy neurons are
labeled with white arrows, whereas neurodegenerated or missing neurons are labeled with red arrows. (Scale bars, 30 μm.) Between 40 and 50 animals were analyzed
per condition in each experiment. Data are shown as means, and error bars are shown as the SE of means; **P < 0.01 and ***P < 0.001.








(12). However, our in vivo experiments demonstrate that this is
not the case for SC-D.
The ability of SC-D to target preformed fibrils might have
important implications for the prion-like pathological spreading
of α-Syn aggregates in the brain (4). By disentangling trans-
missible fibrillary assemblies, SC-D might reduce templated
seeding and thus aggregate-catalyzed conversion of soluble α-Syn
molecules into their insoluble forms. It has been suggested that
to attain a sustainable spreading and prevent dilution of aggre-
gates as they propagate from cell to cell, a process of aggregate
amplification is required, in addition to templated seeding (36).
PMCA emulates these particular conditions in vitro. The po-
tency of SC-D in blocking PMCA-induced amplification of α-Syn
fibrils is thus promising.
SC-D displayed low toxicity for neural cells and displayed
cellular permeability. Indeed, SC-D treatment at concentrations
as low as 1 μM significantly reduced the number of α-Syn in-
clusions and the number of inclusions per cell. These data
prompted us to assess the effects of SC-D treatment in in vivo
models of α-Syn aggregation. First, we selected a well-validated
C. elegans model of PD that expresses human α-Syn in muscular
cells (21). When worms were treated with SC-D at preadult
stages, we observed an important decrease in the number of
α-Syn inclusions and a significant recovery of motility in adult PD
worms. However, independent of whether a compound targets
the early stages of aggregation or disrupts mature protein in-
clusions, or both, the final aim of a PD-oriented therapy is not
to interfere with α-Syn aggregation per se but instead to prevent
the neuronal degeneration associated with this phenomenon. It
is in this therapeutic context where SC-D stands out, since it is
able to increase by more than threefold the number of animals
with intact DA neurons in a C. elegans model in which the
expression of human α-Syn is directly connected to dopami-
nergic degeneration (31).
Conclusions
In the present study, we describe how drug-screening efforts have
crystallized in the discovery of a molecule able to inhibit α-Syn
aggregation, both in vitro and in vivo, without interacting sig-
nificantly with functional, monomeric, and soluble α-Syn. SC-D
is a nontoxic molecule that exhibits a unique capability to in-
teract with and disassemble amyloid fibrils, a property that is
likely connected to its ability to prevent the α-Syn–promoted
degeneration of dopaminergic neurons. Taken together, SC-D
constitutes a very promising lead compound for the develop-
ment of a novel therapeutic molecule for disease modification in
PD and other synucleinopathies.
Materials and Methods
Protein purification, metabolic stability assays, in vitro aggregation studies,
protein-misfolding cyclic amplification, molecular dynamics simulations, NMR
studies, cytotoxicity assays, in-cell aggregation studies, and the C. elegans
models of PD are described in detail in SI Appendix.
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